Equities

Wakamoto Pharmaceutical Co Ltd

4512:TYO

Wakamoto Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)238.00
  • Today's Change0.00 / 0.00%
  • Shares traded114.60k
  • 1 Year change+20.20%
  • Beta0.9842
Data delayed at least 20 minutes, as of Nov 13 2024 05:43 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of JPY
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments3,6653,8793,232
Total Receivables, Net2,8753,2142,811
Total Inventory2,0061,9532,251
Prepaid expenses152122121
Other current assets, total273185193
Total current assets8,9709,3538,608
Property, plant & equipment, net3,0283,0323,297
Goodwill, net------
Intangibles, net357202196
Long term investments2,4422,4832,066
Note receivable - long term------
Other long term assets562567734
Total assets15,42115,71214,953
LIABILITIES
Accounts payable7769611,074
Accrued expenses667920643
Notes payable/short-term debt100100100
Current portion long-term debt/capital leases0.531.061.06
Other current liabilities, total265256190
Total current liabilities1,8082,2392,009
Total long term debt00.531.59
Total debt101102103
Deferred income tax423340205
Minority interest------
Other liabilities, total1,1641,2251,257
Total liabilities3,3953,8053,473
SHAREHOLDERS EQUITY
Common stock3,3963,3963,396
Additional paid-in capital2,6762,6762,676
Retained earnings (accumulated deficit)4,7114,7064,568
Treasury stock - common(36)(36)(36)
Unrealized gain (loss)1,2791,165877
Other equity, total0.000.000.00
Total equity12,02611,90711,481
Total liabilities & shareholders' equity15,42115,71214,953
Total common shares outstanding353535
Treasury shares - common primary issue0.130.130.13
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.